Table 1.

MUC16/CA125 as a clinical marker

Disease species	Expression situation	Representative meaning
Interstitial lung disease	CA125 expression was upregulated	Disease marker
Ovarian cancer	Overexpression	Cancer marker Represents a poor prognosis
Ovarian cancer	CA125 expression was upregulated 3–6 months after treatment	The patient did not respond well to primary treatment
Endometrial carcinoma	HE4 and CA125 increased	Predicting high LNM risk in patients with endometrioid adenocarcinoma before surgery
Epithelial ovarian cancer	CA125 and HE4 were cleared slowly after chemotherapy	Suggests that the patient may be resistant to platinum drugs and the prognosis is poor
Pancreatic cancer	Overexpression	Cancer marker
Acute heart failure	CA125 expression was up-regulated	Represents a poor prognosis
Cancer of unknown primary	Mutation	Cancer marker
EBV-associated lymphoepithelioma-like cholangiocarcinoma	Mutation	Help identify this particular subtype
Primary malignant melanoma of the esophagus	Mutation	Help identify this particular subtype
Pseudomyxoma peritonei	Mutation	Help identify this particular subtype
Ovarian serous cystadenocarcinoma	The RNA levels of MUC16, PAX8 and SOX17 genes were changed	Distinguish ovarian serous cystadenocarcinoma from other tumor types
Gastric cancer	Mutation	Represents higher TML and longer median survival, and higher response to immunotherapy
Colon cancer	Mutation	Represents high TMB
Non-small cell lung cancer	Mutation	It is associated with increased mutation load TMB and neoantigen load It indicates better effect of ICI treatment
Melanoma	Mutation	Represents high TMB It indicates better effect of ICI treatment